Peijia Medical's partner JenaValve was fully acquired by Edwards Lifesciences.
On July 24, 2024, Peijia Medical (9996.HK) partner JenaValve Technology, Inc. (hereinafter referred to as JenaValve) announced an agreement with U.S. medical device giant Edwards Lifesciences (NYSE: EW, referred to as "Edwards"). Edwards Lifesciences will fully acquire JenaValve. After the transaction, Peijia Medical will continue to hold exclusive rights to the JenaValve Trilogy THV system in Greater China.
On March 28, 2024, the one-year clinical data from the pivotal ALIGN-AR trial of JenaValve Trilogy™, the world's first aortic valve regurgitation treatment system featuring the innovative Locators design, was published in the renowned medical journal The Lancet, with encouraging results. The publication of ALIGN-AR trial data marks a significant milestone in transcatheter aortic valve replacement for aortic regurgitation, ushering in a new era of minimally invasive treatment for high-risk surgical patients with symptomatic moderate-to-severe or severe aortic regurgitation.
At the end of 2021, Peijia Medical signed an exclusive license with JenaValve for the TrilogyTM heart valve system in Greater China and became a minority shareholder of JenaValve. Subsequently, Peijia Medical rebranded the technology as TaurusTrioTM Transcatheter Aortic Valve System, conducted registration clinical trials in China, and successfully completed patient enrollment in January 2024, entering the one-year follow-up phase.
"As a partner of JenaValve, Peijia Medical congratulates JenaValve and Edwards Lifesciences on announcing this transformative collaboration in the structural heart field," said Dr. Yi Zhang, Chairman and CEO of Peijia Medical. The publication of ALIGN-AR trial results in The Lancet swiftly shifted global physicians' understanding of aortic regurgitation treatment. Edwards' high-value acquisition of JenaValve represents the highest recognition of the product, technology, and therapy, significantly accelerating the global advancement of transcatheter aortic regurgitation treatment.
Under the acquisition agreement, Peijia Medical will retain exclusive rights to the JenaValve Trilogy THV system in Greater China post-transaction. Edwards Lifesciences' acquisition will enhance global physician awareness of aortic regurgitation and accelerate the development of the JenaValve Trilogy THV system. After closing, the company will collaborate with Edwards Lifesciences to deliver the latest and best treatment solutions for aortic regurgitation patients in their respective markets.
This acquisition marks another breakthrough in Edwards' transcatheter valve portfolio, with recent major advancements across key areas including tricuspid valve replacement, mitral valve therapies, lifetime management/durable valves, and aortic regurgitation. As a leader in China's structural heart intervention field, Peijia Medical has also strategically developed a comprehensive pipeline: transvascular tricuspid replacement MonarQ, transseptal mitral replacement HighLife, edge-to-edge mitral/tricuspid repair GeminiOne, durable dry valve TaurusNXT, polymer valves, and aortic regurgitation treatment TaurusTrio, continuously addressing global clinical demands for transcatheter valve therapies.
As an innovator in structural heart disease, Peijia Medical began its aortic regurgitation technology strategy years ago. With evidence-based results now published, what appears as natural success stems from early management's technical vision. The company believes deep technical understanding enhances pipeline uniqueness, competitiveness, and external investment success. With a pipeline rivaling global giants, Peijia anticipates more products will soon bear fruit.
"We look forward to meaningful collaborations with international peers like Edwards. We also hope industry leaders will notice Peijia's wholly-owned tricuspid replacement MonarQ and locally developed edge-to-edge repair system GeminiOne," said Dr. Zhang, expressing absolute confidence in China's R&D capabilities through persistent, step-by-step progress.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
